Luc Christiaens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luc Christiaens has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Claire Bouleti
Cardiology Department, University Hospital of Poitiers, Clinical Investigation Center (Inserm 1402), Poitiers, France
5 shared publications - Benjamin Alos
Cardiology Department, CHU Poitiers , 2, Rue de la Milétrie, Poitiers F-86021
4 shared publications - Rodrigue Garcia
Cardiology Department & Centre d'Investigation Clinique 1402, University Hospital Centre Poitiers, Poitiers, France
4 shared publications - François Le Gal
Department of Anesthesia and Critical Care, University Hospital of Poitiers, Poitiers, France
3 shared publications Alain Furber
Institut MITOVASC, UMR INSERM U1083 and CNRS 6015, Équipe Physiopathologie Cardiovasculaire, Service de Cardiologie, CHU d'Angers, Université Angers, 49000 Angers, France
2 shared publications- Anthony Li
City St George’s, University of London, United Kingdom (M.C.W., A.C.L., M.M.S.).
2 shared publications
Latest Publications
- 10 June 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (12) , 1056-1065
Heart Rate and Cardiovascular Outcomes in Post–Myocardial Infarction Patients Treated by β-Blockers: A Secondary Analysis of the ABYSS Trial
BACKGROUND: Heart rate (HR) is a key prognostic factor after myocardial infarction (MI), but its relevance in the modern reperfusion era is uncertain. We aim to evaluate the association between HR and β-blocker interruption on cardiovascular outcomes. METHODS: A prespecified secondary analysis of the ABYSS trial (Assessment of Beta-Blocker Interruption 1 Year After an Uncomplicted Myocardial Infarction), including 3698 stable post-MI patients (left ventricular ejection fraction ≥40%) randomized to continue or interrupt β-blockers, was conducted. Patients were grouped by prerandomization HR tertiles: P= 0.867). Higher HR was associated with increased risk of death, MI, or stroke (5.5% versus 6.4% versus 9.2%; P 50%). CONCLUSIONS: In stabilized post-MI patients with preserved ejection fraction, higher HR remains associated with adverse cardiovascular events and mortality in the reperfusion era. Interrupting β-blockers substantially increases HR and is consistently linked with worse outcomes irrespective of baseline HR, supporting continuation of β-blocker therapy.
- 10 June 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (12) , 1056-1065
Heart Rate and Cardiovascular Outcomes in Post–Myocardial Infarction Patients Treated by β-Blockers: A Secondary Analysis of the ABYSS Trial
BACKGROUND: Heart rate (HR) is a key prognostic factor after myocardial infarction (MI), but its relevance in the modern reperfusion era is uncertain. We aim to evaluate the association between HR and β-blocker interruption on cardiovascular outcomes. METHODS: A prespecified secondary analysis of the ABYSS trial (Assessment of Beta-Blocker Interruption 1 Year After an Uncomplicted Myocardial Infarction), including 3698 stable post-MI patients (left ventricular ejection fraction ≥40%) randomized to continue or interrupt β-blockers, was conducted. Patients were grouped by prerandomization HR tertiles: P= 0.867). Higher HR was associated with increased risk of death, MI, or stroke (5.5% versus 6.4% versus 9.2%; P 50%). CONCLUSIONS: In stabilized post-MI patients with preserved ejection fraction, higher HR remains associated with adverse cardiovascular events and mortality in the reperfusion era. Interrupting β-blockers substantially increases HR and is consistently linked with worse outcomes irrespective of baseline HR, supporting continuation of β-blocker therapy.
- 25 October 2025
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 119 (2) , 137-143
Rationale and design of the imaging for detection rate of cardiac transthyretin amyloidosis study (the IMPACT study)
- 25 October 2025
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 119 (2) , 137-143
Rationale and design of the imaging for detection rate of cardiac transthyretin amyloidosis study (the IMPACT study)
- Open Access
- 1 October 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (Supplement)
CT signs of pulmonary hypertension before TAVI: long-term prognosis in a cohort of 469 patients
Introduction: Patients undergoing TAVI often present with comorbidities, such as pulmonary hypertension (PH), which has been shown to be predictive of poor outcome after TAVI, using echocardiography (TTE). CT scan is systematically performed before TAVI, and PH signs on CT may be used to assess long-term survival after TAVI, but data are scarce on this matter. Purpose: The main objective of this study was to analyze the association between signs suggestive of PH on CT performed before TAVI and 4-years mortality. Methods: Between 2013 and 2018, 469 consecutive patients undergoing TAVI at our institution were included. We analyzed all pre-procedural CT for signs of PH: pulmonary artery (PA) diameter, PA to aorta (PA/A) ratio, right ventricle (RV) basal diameter, and inferior vena cava (IVC) diameter, with double reading, blinded to clinical and echocardiographic data. Results: Our population of elderly patients (mean age 85±6) having a severe aortic stenosis was highly symptomatic (NYHA III–IV in 71% of cases) with moderate PH on TTE (mean sPAP of 43±14 mmHg), and intermediate operative risk (STS-score 6.2±4.5%). After a median follow-up of 4 years after TAVI, multivariate analysis identified IVC and RV axial diameters as CT PH parameters associated with long term mortality (adjusted HR and 95% CI of 1.08 [1.05–1.10] (p<0.0001) and 1.03 [1.01–1,05] (p=0.002), respectively). An IVC diameter ≥20 mm and a RV axial diameter ≥37 mm on CT were independently associated with late mortality, with areas under the curve (AUC) of 0.75; IC95% (0.70–0.80) and 0.67 (0.62–0.72), better than any significant clinical or biological data and than echocardiographic sPAP (Figure 1). 4-year survival was 65±4% if IVC <20 mm vs 44±3% if IVC ≥20 mm (p<0.0001) (Figure 2), and 35±4% if RV <37 mm vs 54±5% if RV ≥37 mm (p<0.0001). Interestingly, TTE IVC diameters were not significantly associated with long-term mortality and could not be assessed in 66 patients (14%) due to poor abdominal echogenicity. On the 403 patients with IVC diameters, assessed both by TTE and CT scan, correlation was poor although significant (R2= 0.1), with significant differences between the 2 methods using a paired T test (17.3±5.4 mm versus 20.3±6.0; P<0.001). Moreover, on the 403 patients, the discrimination was far better with CT scan IVC diameters than with TTE diameters: 0.75 (0.70–0.80) vs 0.54 (0.48–0.59); p<0.001. Regarding RV diameter, too many data were missing on TTE to compare their prognostic impact with CT diameters. Conclusion: This study is the first to outline IVC and RV diameters on preprocedural CT as being associated to long-term mortality after TAVI. They outperformed other clinical, biological and TTE prognostic factors as well as the usual operative risk scores in terms of discrimination. These simple measurements, which can be performed on any pre-TAVI CT, could therefore be included in routine practice to improve the selection of patients undergoing TAVI. Funding Acknowledgement: Type of funding sources: None.
- 1 October 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (Supplement)
Open AccessCT signs of pulmonary hypertension before TAVI: long-term prognosis in a cohort of 469 patients
Introduction: Patients undergoing TAVI often present with comorbidities, such as pulmonary hypertension (PH), which has been shown to be predictive of poor outcome after TAVI, using echocardiography (TTE). CT scan is systematically performed before TAVI, and PH signs on CT may be used to assess long-term survival after TAVI, but data are scarce on this matter. Purpose: The main objective of this study was to analyze the association between signs suggestive of PH on CT performed before TAVI and 4-years mortality. Methods: Between 2013 and 2018, 469 consecutive patients undergoing TAVI at our institution were included. We analyzed all pre-procedural CT for signs of PH: pulmonary artery (PA) diameter, PA to aorta (PA/A) ratio, right ventricle (RV) basal diameter, and inferior vena cava (IVC) diameter, with double reading, blinded to clinical and echocardiographic data. Results: Our population of elderly patients (mean age 85±6) having a severe aortic stenosis was highly symptomatic (NYHA III–IV in 71% of cases) with moderate PH on TTE (mean sPAP of 43±14 mmHg), and intermediate operative risk (STS-score 6.2±4.5%). After a median follow-up of 4 years after TAVI, multivariate analysis identified IVC and RV axial diameters as CT PH parameters associated with long term mortality (adjusted HR and 95% CI of 1.08 [1.05–1.10] (p<0.0001) and 1.03 [1.01–1,05] (p=0.002), respectively). An IVC diameter ≥20 mm and a RV axial diameter ≥37 mm on CT were independently associated with late mortality, with areas under the curve (AUC) of 0.75; IC95% (0.70–0.80) and 0.67 (0.62–0.72), better than any significant clinical or biological data and than echocardiographic sPAP (Figure 1). 4-year survival was 65±4% if IVC <20 mm vs 44±3% if IVC ≥20 mm (p<0.0001) (Figure 2), and 35±4% if RV <37 mm vs 54±5% if RV ≥37 mm (p<0.0001). Interestingly, TTE IVC diameters were not significantly associated with long-term mortality and could not be assessed in 66 patients (14%) due to poor abdominal echogenicity. On the 403 patients with IVC diameters, assessed both by TTE and CT scan, correlation was poor although significant (R2= 0.1), with significant differences between the 2 methods using a paired T test (17.3±5.4 mm versus 20.3±6.0; P<0.001). Moreover, on the 403 patients, the discrimination was far better with CT scan IVC diameters than with TTE diameters: 0.75 (0.70–0.80) vs 0.54 (0.48–0.59); p<0.001. Regarding RV diameter, too many data were missing on TTE to compare their prognostic impact with CT diameters. Conclusion: This study is the first to outline IVC and RV diameters on preprocedural CT as being associated to long-term mortality after TAVI. They outperformed other clinical, biological and TTE prognostic factors as well as the usual operative risk scores in terms of discrimination. These simple measurements, which can be performed on any pre-TAVI CT, could therefore be included in routine practice to improve the selection of patients undergoing TAVI. Funding Acknowledgement: Type of funding sources: None.
- Open Access
- 1 October 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (Supplement)
Normal indexed values of left atrial volume by age and gender in a population of 250 healthy subjects: a CT-study
Left atrial volume (LAV) is predictive of cardiovascular outcomes. Its reference values have been described with 2D-transthoracic echocardiography (TTE) and cardiac MRI but very few data are published regarding cardiac computed tomography angiography (CCTA) values. Recent guidelines have highlighted the role of CT-scan, which is a valuable tool to evaluate cardiac dimensions, by its volumetric approach, with a minimal time acquisition and high reproducibility. We aimed to provide CCTA normal LAV reference values by age and gender in a population of 250 healthy subjects. We retrospectively included 250 adults (18–74 years) who underwent a retrospectively ECG-gated CCTA in our institution, in order to rule out coronary disease after an episode of chest pain, without any history of cardiac disease or anomaly on the CT-scan. We divided our population in 5 classes of age (2 (lower and upper limits 25 and 76 ml/m2 respectively) by 3D method and slightly lower using A-L method (42.8±11.5 ml/m2) (LL and UL 20 and 66 ml/m2 respectively). Normal values were 22–81 ml/m2 (3D) and 17–68 ml/m2 (A-L) in men and 30–70 ml/m2 (3D) and 23–63 ml/m2 (A-L) in women. There was no significant difference across genders, but LAV significantly increased with age by the 2 methods (Table 1). Interobserver agreement was better using 3D than A-L method (Lin's coefficient = 0.89 and 0.67, respectively). Concordance between the 2 methods was good, with overall Pearson's correlation coefficient R = 0.72 (p<0.001) (Figure 1). This study is the first to establish normal indexed LAV values by gender and age in a large population of healthy adults with 2 methods, 3D volumetric approach being the most reproducible one. More accurate than TTE and more available than CMR, CCTA may become a reference method to evaluate LAV in various cardiac diseases and normal values definition is thus of importance. Type of funding sources: None. Table 1. Indexed 3D and area-length LAV by gender Figure 1. Correlation between 3D and A-L methods
- 1 October 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (Supplement)
Open AccessNormal indexed values of left atrial volume by age and gender in a population of 250 healthy subjects: a CT-study
Left atrial volume (LAV) is predictive of cardiovascular outcomes. Its reference values have been described with 2D-transthoracic echocardiography (TTE) and cardiac MRI but very few data are published regarding cardiac computed tomography angiography (CCTA) values. Recent guidelines have highlighted the role of CT-scan, which is a valuable tool to evaluate cardiac dimensions, by its volumetric approach, with a minimal time acquisition and high reproducibility. We aimed to provide CCTA normal LAV reference values by age and gender in a population of 250 healthy subjects. We retrospectively included 250 adults (18–74 years) who underwent a retrospectively ECG-gated CCTA in our institution, in order to rule out coronary disease after an episode of chest pain, without any history of cardiac disease or anomaly on the CT-scan. We divided our population in 5 classes of age (2 (lower and upper limits 25 and 76 ml/m2 respectively) by 3D method and slightly lower using A-L method (42.8±11.5 ml/m2) (LL and UL 20 and 66 ml/m2 respectively). Normal values were 22–81 ml/m2 (3D) and 17–68 ml/m2 (A-L) in men and 30–70 ml/m2 (3D) and 23–63 ml/m2 (A-L) in women. There was no significant difference across genders, but LAV significantly increased with age by the 2 methods (Table 1). Interobserver agreement was better using 3D than A-L method (Lin's coefficient = 0.89 and 0.67, respectively). Concordance between the 2 methods was good, with overall Pearson's correlation coefficient R = 0.72 (p<0.001) (Figure 1). This study is the first to establish normal indexed LAV values by gender and age in a large population of healthy adults with 2 methods, 3D volumetric approach being the most reproducible one. More accurate than TTE and more available than CMR, CCTA may become a reference method to evaluate LAV in various cardiac diseases and normal values definition is thus of importance. Type of funding sources: None. Table 1. Indexed 3D and area-length LAV by gender Figure 1. Correlation between 3D and A-L methods
- 1 June 2021
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 102 (6) , 337-345
Position paper on stress cardiac MRI in chronic coronary syndrome: Endorsed by the Société Française de Radiologie (SFR) the Société Française d’Imagerie CardioVasculaire (SFICV) and the Société Française de Cardiologie (SFC)
- 1 June 2021
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 102 (6) , 337-345
Position paper on stress cardiac MRI in chronic coronary syndrome: Endorsed by the Société Française de Radiologie (SFR) the Société Française d’Imagerie CardioVasculaire (SFICV) and the Société Française de Cardiologie (SFC)
- Open Access
- 27 May 2021
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 23 (5) , e26349
Virtual Reality for Sedation During Atrial Fibrillation Ablation in Clinical Practice: Observational Study
Background: Connected devices are dramatically changing many aspects in health care. One such device, the virtual reality (VR) headset, has recently been shown to improve analgesia in a small sample of patients undergoing transcatheter aortic valve implantation. Objective: We aimed to investigate the feasibility and effectiveness of VR in patients undergoing atrial fibrillation (AF) ablation under conscious sedation. Methods: All patients who underwent an AF ablation with VR from March to May 2020 were included. Patients were compared to a consecutive cohort of patients who underwent AF ablation in the 3 months prior to the study. Primary efficacy was assessed by using a visual analog scale, summarizing the overall pain experienced during the ablation. Results: The AF cryoablation procedure with VR was performed for 48 patients (mean age 63.0, SD 10.9 years; n=16, 33.3% females). No patient refused to use the device, although 14.6% (n=7) terminated the VR session prematurely. Preparation of the VR headset took on average 78 (SD 13) seconds. Compared to the control group, the mean perceived pain, assessed with the visual analog scale, was lower in the VR group (3.5 [SD 1.5] vs 4.3 [SD 1.6]; P=.004), and comfort was higher in the VR group (7.5 [SD 1.6] vs 6.8 [SD 1.7]; P=.03). On the other hand, morphine consumption was not different between the groups. Lastly, complications, as well as procedure and fluoroscopy duration, were not different between the two groups. Conclusions: We found that VR was associated with a reduction in the perception of pain in patients undergoing AF ablation under conscious sedation. Our findings demonstrate that VR can be easily incorporated into the standard ablation workflow.
- 27 May 2021
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 23 (5) , e26349
Open AccessVirtual Reality for Sedation During Atrial Fibrillation Ablation in Clinical Practice: Observational Study
Background: Connected devices are dramatically changing many aspects in health care. One such device, the virtual reality (VR) headset, has recently been shown to improve analgesia in a small sample of patients undergoing transcatheter aortic valve implantation. Objective: We aimed to investigate the feasibility and effectiveness of VR in patients undergoing atrial fibrillation (AF) ablation under conscious sedation. Methods: All patients who underwent an AF ablation with VR from March to May 2020 were included. Patients were compared to a consecutive cohort of patients who underwent AF ablation in the 3 months prior to the study. Primary efficacy was assessed by using a visual analog scale, summarizing the overall pain experienced during the ablation. Results: The AF cryoablation procedure with VR was performed for 48 patients (mean age 63.0, SD 10.9 years; n=16, 33.3% females). No patient refused to use the device, although 14.6% (n=7) terminated the VR session prematurely. Preparation of the VR headset took on average 78 (SD 13) seconds. Compared to the control group, the mean perceived pain, assessed with the visual analog scale, was lower in the VR group (3.5 [SD 1.5] vs 4.3 [SD 1.6]; P=.004), and comfort was higher in the VR group (7.5 [SD 1.6] vs 6.8 [SD 1.7]; P=.03). On the other hand, morphine consumption was not different between the groups. Lastly, complications, as well as procedure and fluoroscopy duration, were not different between the two groups. Conclusions: We found that VR was associated with a reduction in the perception of pain in patients undergoing AF ablation under conscious sedation. Our findings demonstrate that VR can be easily incorporated into the standard ablation workflow.
- 1 April 2021
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 114 (4) , 325-335
Position paper on stress cardiac magnetic resonance imaging in chronic coronary syndrome: Endorsed by the Société française de radiologie (SFR), the Société française d’imagerie cardiovasculaire (SFICV) and the Société française de cardiologie (SFC)
- 1 April 2021
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 114 (4) , 325-335
Position paper on stress cardiac magnetic resonance imaging in chronic coronary syndrome: Endorsed by the Société française de radiologie (SFR), the Société française d’imagerie cardiovasculaire (SFICV) and the Société française de cardiologie (SFC)
- 19 March 2021
- Published by Elsevier
- p. 117-122
Sécurité, précautions et surveillance
- Open Access
- 8 December 2020
- Published by JMIR Publications Inc. in JMIR Preprints
Virtual Reality for Sedation During Atrial Fibrillation Ablation in Clinical Practice: Observational Study (Preprint)
BACKGROUND Connected devices are dramatically changing many aspects in health care. One such device, the virtual reality (VR) headset, has recently been shown to improve analgesia in a small sample of patients undergoing transcatheter aortic valve implantation. OBJECTIVE We aimed to investigate the feasibility and effectiveness of VR in patients undergoing atrial fibrillation (AF) ablation under conscious sedation. METHODS All patients who underwent an AF ablation with VR from March to May 2020 were included. Patients were compared to a consecutive cohort of patients who underwent AF ablation in the 3 months prior to the study. Primary efficacy was assessed by using a visual analog scale, summarizing the overall pain experienced during the ablation. RESULTS The AF cryoablation procedure with VR was performed for 48 patients (mean age 63.0, SD 10.9 years; n=16, 33.3% females). No patient refused to use the device, although 14.6% (n=7) terminated the VR session prematurely. Preparation of the VR headset took on average 78 (SD 13) seconds. Compared to the control group, the mean perceived pain, assessed with the visual analog scale, was lower in the VR group (3.5 [SD 1.5] vs 4.3 [SD 1.6]; P=.004), and comfort was higher in the VR group (7.5 [SD 1.6] vs 6.8 [SD 1.7]; P=.03). On the other hand, morphine consumption was not different between the groups. Lastly, complications, as well as procedure and fluoroscopy duration, were not different between the two groups. CONCLUSIONS We found that VR was associated with a reduction in the perception of pain in patients undergoing AF ablation under conscious sedation. Our findings demonstrate that VR can be easily incorporated into the standard ablation workflow.
- 8 December 2020
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessVirtual Reality for Sedation During Atrial Fibrillation Ablation in Clinical Practice: Observational Study (Preprint)
BACKGROUND Connected devices are dramatically changing many aspects in health care. One such device, the virtual reality (VR) headset, has recently been shown to improve analgesia in a small sample of patients undergoing transcatheter aortic valve implantation. OBJECTIVE We aimed to investigate the feasibility and effectiveness of VR in patients undergoing atrial fibrillation (AF) ablation under conscious sedation. METHODS All patients who underwent an AF ablation with VR from March to May 2020 were included. Patients were compared to a consecutive cohort of patients who underwent AF ablation in the 3 months prior to the study. Primary efficacy was assessed by using a visual analog scale, summarizing the overall pain experienced during the ablation. RESULTS The AF cryoablation procedure with VR was performed for 48 patients (mean age 63.0, SD 10.9 years; n=16, 33.3% females). No patient refused to use the device, although 14.6% (n=7) terminated the VR session prematurely. Preparation of the VR headset took on average 78 (SD 13) seconds. Compared to the control group, the mean perceived pain, assessed with the visual analog scale, was lower in the VR group (3.5 [SD 1.5] vs 4.3 [SD 1.6]; P=.004), and comfort was higher in the VR group (7.5 [SD 1.6] vs 6.8 [SD 1.7]; P=.03). On the other hand, morphine consumption was not different between the groups. Lastly, complications, as well as procedure and fluoroscopy duration, were not different between the two groups. CONCLUSIONS We found that VR was associated with a reduction in the perception of pain in patients undergoing AF ablation under conscious sedation. Our findings demonstrate that VR can be easily incorporated into the standard ablation workflow.
- 1 September 2020
- Published by Elsevier in International Journal of Cardiology
- Vol. 314, 64-69
Prognostic value of Charlson Comorbidity Index in the elderly with a cardioverter defibrillator implantation
- 1 September 2020
- Published by Elsevier in International Journal of Cardiology
- Vol. 314, 64-69
Prognostic value of Charlson Comorbidity Index in the elderly with a cardioverter defibrillator implantation